Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival

Bristol-Myers Squibb’s study met its co-primary endpoint of overall survival with Opdivo® (nivolumab) plus low dose Yervoy® (ipilimumab) vs. chemotherapy in first-line Non-Small Cell Lung Cancer patients whose tumors expressed PD-L1 ≥1%. This is the third tumor type in which Opdivo plus Yervoy demonstrates overall survival benefit in a Phase 3 Trial. Learn more HERE

Victoria has blogged 1630 posts